Eagle Pharmaceuticals, Inc. Press Releases

EGRX 
$37.68
*  
3.68
10.82%
Get EGRX Alerts
*Delayed - data as of Mar. 2, 2015  -  Find a broker to begin trading EGRX now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
FDA Grants Seven Years’ Market Exclusivity to Eagle Pharmaceuticals’ Ryanodex for the Treatment of Malignant Hyperthermia
2/23/2015 10:24:00 AM - Business Wire


Eagle Pharmaceuticals, Inc. Reports Financial Results for Three Month Period Ended December 31, 2014
2/17/2015 4:01:00 PM - Business Wire


Eagle Pharmaceuticals to Hold Conference Call at 8:30 a.m. EST Today to Discuss Licensing Agreement with Teva to Commercialize Eagle’s Rapid Infusion Bendamustine
2/17/2015 7:05:00 AM - Business Wire


Eagle Pharmaceuticals to Hold Conference Call at 8:30 a.m. EST Today to Discuss Licensing Agreement with Teva to Commercialize Eagle’s Rapid Infusion Bendamustine
2/17/2015 7:05:00 AM - Business Wire


Teva and Eagle Pharmaceuticals Announce Teva’s License to Commercialize Eagle’s Bendamustine Rapid Infusion Product
2/17/2015 7:00:00 AM - Business Wire


Eagle Pharmaceuticals, Inc. Announces Change in Fiscal Year End
1/20/2015 9:20:00 AM - Business Wire
▲136.98 % Price Change since this news event. The Volume Ratio is 2.19.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Year End 2014 Financial Results
12/17/2014 7:38:00 AM - Business Wire


Eagle Pharmaceuticals to Discuss 2014 Fourth Quarter and Year-End Financial Results on December 17, 2014
12/4/2014 5:56:00 PM - Business Wire
▲190.07 % Price Change since this news event. The Volume Ratio is 2.75.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day